Traditional Chinese herb, Astragalus: possible for treatment and prevention of COVID-19?

Author:

Law Siukan1ORCID,Lo Chuiman1ORCID,Han Jie1ORCID,Leung Albert Wingnang2ORCID,Xu Chuanshan3ORCID

Affiliation:

1. Department of Science, School of Science and Technology , The Open University of Hong Kong Ho Man Tin , Kowloon , Hong Kong

2. School of Graduate Studies , Lingnan University , Tuen Mun , Hong Kong

3. Key Laboratory of Molecular Target and Clinical Pharmacology State Key Laboratory of Respiratory Diseases , School of Pharmaceutical Sciences & Fifth Affiliated Hospital Guangzhou Medical University , Guangzhou 511436 , China

Abstract

Summary Astragalus is a traditional herb which has been used in China for a long time. It regulates blood circulation (vital energy), invigorates body fluid circulation, protects the flow of blood to fight against the attack of pathogens, and strengthens “blood deficiencies” according to Bencao Congxin. Astragalus was approved by the Food and Drug Administration in 2009 as a dietary supplement for upper respiratory infections, allergic rhinitis (hay fever), asthma, chronic fatigue syndrome, and chronic kidney disease. Thirty journals published in the past ten years were reviewed by using library search engines such as SCI/SCIE, PubMed, and Scopus. In this mini-review, we focus on the anti-inflammatory of Astragalus features, discuss the background of Astragalus and its function in various diseases from water-extracted Astragalus membranaceus, Astragalus saponins, and Astragalus polysaccharides. Based on the traditional Chinese medicine theory, Astragalus is a potential candidate to treat and prevent COVID-19.

Publisher

Walter de Gruyter GmbH

Reference29 articles.

1. 1. WHO announces COVID-19 outbreak a pandemic, 2020. https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic (accessed 29 Aug 2020).

2. 2. Zhao S, Lin Q, Ran J, Musa SS, Yang G, Lou YJ, et al. Preliminary estimation of basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak. Int J Infect Dis 2020; 92:214-217. doi: http://dx.doi.org/10.1016/j.ijid.2020.01.05010.1016/j.ijid.2020.01.050

3. 3. COVID-19 Coronavirus pandemic, 2020. https://www.worldometers.info/coronavirus/?utm_campaign=homeAdUOA?Si (accessed 29 Aug 2020).

4. 4. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed 2020. N Engl J Med 2020; 382(21):1969-1973. doi: http://dx.doi.org/10.1056/NEJMp200563010.1056/NEJMp2005630

5. 5. National health commission of the People’s Republic of China, Guideline on diagnosis and treatment of COVID-19 (Trial 7th edition), 2020. Available from: http://en.nhc.gov.cn/2020-03/29/c_78469.htm (accessed 29 Aug 2020).

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3